Wed, January 19, 2022

Madhu Kumar Upgraded (ARWR) to Strong Buy on, Jan 19th, 2022

Madhu Kumar of Goldman Sachs, Upgraded "Arrowhead Pharmaceuticals, Inc." (ARWR) to Strong Buy on, Jan 19th, 2022.

Madhu has made no other calls on ARWR in the last 4 months.



There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, all agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $45 on, Tuesday, November 23rd, 2021